Professor Anna Norhammar
Karolinska Institute, Stockholm (Sweden)
Member of:
/f/125658/7246x3240/f72d1f6fc5/esc-logo-lock-up-red-pos-rgb.png){kind=logo}
SGLT2 inhibitors and atherosclerosis-related outcomes: the good and the bad
Event: ESC Congress 2019
Topic: Diabetes and the Heart
Session: SGLT2 inhibitors and cardiovascular outcomes
State of the Art in antidiabetic treatment to prevent CVD
Event: ESC Congress 2019
Topic: Pharmacotherapy
Session: The right glucose-lowering drugs for the right patient
Heart failure and death in new users of SGLT2 inhibitors vs other glucose-lowering drugs - consistent risk reduction across patient groups in 4 countries and >270,000 patients: The CVD-REAL Study
Event: ESC Congress 2017
Topic: Heart failure, other
Session: Late-Breaking Science in Heart Failure
Dapagliflozin is associated with lower risk of hospitalization for heart failure, major adverse cardiovascular events and all-cause death compared to DPP-4i in T2D patients: CVD-REAL Nordic
Event: Heart Failure 2017 - 4th World Congress on Acute Heart Failure
Topic: Population studies / Epidemiology
Session: Clinical Forum - Sat. 29 April 08:30 - Tues. 02 May at 12:30
Periodontal disease - A potential risk factor for myocardial infarction in younger women
Event: ESC Congress 2016
Topic: Epidemiology, lipids
Session: Cardiovascular risk in populations
ESC 365 is supported by
